Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

The market just wobbled. Will it fall down?
Markets Opinion

The market just wobbled. Will it fall down?

Recent losses can be explained by one word: speculation.

RBNZ says risks linked to new mortgage lending contained
Economy

RBNZ says risks linked to new mortgage lending contained

House prices near the top of RBNZ's range of sustainable estimates.

Inside ACC's $180m small cap strategy
Markets

Inside ACC's $180m small cap strategy

In one $1 billion portfolio, it's the small caps driving performance.

Employment data dominates quiet day on NZ sharemarket
Markets

Employment data dominates quiet day on NZ sharemarket

The NZ sharemarket was down with no real trend driving the change.

Tom Raynel 05 Nov 2025